Ionis Pharmaceuticals, Inc. Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value
Ionis Pharmaceuticals, Inc. (IONS) had Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value of $225.96 million as of 2020-09-30, per its 10-Q filed 2020-11-04.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue · last filed 2020-11-04
- 2020-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $225.96M.
- 2020-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $276.68M.
- 2020-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $851.16M.
- 2019-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $435.13M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value |
|---|---|
| 2020-09-30 | $225.96M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $276.68M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $851.16M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $435.13M 10-K · filed 2020-03-02 |
| 2019-09-30 | $557.10M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $583.09M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $898.58M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $1.58B 10-K · filed 2019-03-01 |
| 2018-09-30 | $1.37B 10-Q · filed 2018-11-06 |
| 2018-06-30 | $1.17B 10-Q · filed 2018-08-07 |
| 2018-03-31 | $805.58M 10-Q · filed 2018-05-07 |
| 2017-12-31 | $879.67M 10-K · filed 2018-02-28 |
| 2017-09-30 | $714.01M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $637.73M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $649.20M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $463.61M 10-K · filed 2017-03-01 |
| 2016-09-30 | $349.04M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $207.93M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $344.85M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $587.12M 10-K · filed 2016-02-26 |
| 2015-09-30 | $409.24M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $425.72M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $259.87M 10-Q · filed 2015-05-05 |
| 2014-12-31 | $398.49M 10-K · filed 2015-03-02 |
| 2014-09-30 | $253.83M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $214.56M 10-Q · filed 2014-08-04 |
| 2014-03-31 | $213.20M 10-Q · filed 2014-05-06 |
| 2013-12-31 | $282.23M 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |